Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol THYROPED

Next Previous
Trial Profile

A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol THYROPED

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iodixanol (Primary) ; Iohexol (Primary) ; Iopromide (Primary) ; Ioversol (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions
  • Acronyms THYROPED
  • Sponsors GE Healthcare

Most Recent Events

  • 13 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 25 Jun 2021 Planned initiation date changed from 1 Mar 2021 to 1 Mar 2022.
  • 18 May 2020 Planned initiation date changed from 1 Nov 2019 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top